Clarametyx Biosciences
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Respiratory
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting the biofilm—a protective layer around bacteria that drives inflammation and disease exacerbation. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which has completed a successful Phase 2a study in cystic fibrosis, and CMTX-301, which is in preclinical development.
Company HQ City:
Columbus
Company HQ State:
OH
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
CMTX-101, immune-enabling antibody targeting bacterial biofilms
CEO
David Richards
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
Mid-2026
What is your next catalyst (value inflection) update?
Complete Phase 2a data readout, FDA alignment on next trial, Series B planned in 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}